Search
Search
Close this search box.

Bill Aims to Establish Regulatory Framework for CBD as a Supplement

Senator Ron Wyden (D-OR) has reintroduced a bill that aims to establish U.S. Food and Drug Administration (FDA) regulatory framework for CBD as a dietary supplement or food and beverage additive.

Alongside Sens. Rand Paul (R-KY) and Jeff Merkley (D-OR), Wyden announced the reintroduction of The Hemp Access and Consumer Safety Act.

The U.S. Hemp Roundtable has said that it strongly endorses this legislation and applauds Sen. Wyden and his Congressional colleagues for championing efforts to regulate CBD products in the Senate.

Jonathan Miller, General Counsel of the U.S. Hemp Roundtable stated: “We commend Senator Ron Wyden for reintroducing The Hemp Access and Consumer Safety Act, a crucial piece of legislation that addresses the pressing need for FDA regulation of CBD.

READ MORE: Missouri Will Conduct Marijuana Business Demographic Survey Amid Criticism That Black People Are Being Left Out Of Industry

“This bill provides a much needed pathway for FDA to establish a clear and consistent framework for the production, marketing, and sale of hemp-derived CBD to ensure consumer safety while fostering a thriving, regulated market. We look forward to supporting his efforts and appreciate his longtime commitment to unlocking the full potential of the hemp industry.”

The Hemp Access and Consumer Safety Act of 2023 is also being endorsed by national advocacy organizations including We Are For Better Alternatives (WAFBA), the American Herbal Products Association (AHPA), the Hemp Industries Association (HIA), National Hemp Growers Association, Realm of Caring, U.S. Hemp Authority (USHA) and Veterinary Cannabis Society, along with regional and state-based groups such as the Midwest Hemp Council, Colorado Hemp Association, Kentucky Hemp Association, Georgia Hemp Association, iHemp Michigan,  South Dakota Industrial Hemp Association, and the Virginia Hemp Coalition.


⏰ Pre-order discount ends Jan 15
-- Days
-- Hours
-- Mins
Data packs delivered January 2026
🔬 New Report Due January 2026

Global Medical Cannabis Market Review 2026

A comprehensive analysis of the international medical cannabis supply chain — examining country-specific data on exports, imports, market size, domestic production, and distribution landscapes. Understand the driving forces behind global supply dynamics, the impact of telemedicine on patient access, and regulatory changes shaping the market.

What's covered

  • 📊 Global supply chain overview — understand export/import dynamics and domestic production capabilities
  • 🌍 8 export country snapshots — Canada, Portugal, Denmark, North Macedonia, Spain, Australia, Czech Republic, South Africa
  • 👥 6 patient market snapshots — Australia, Germany, UK, Poland, Brazil, France
  • 🔮 Key themes — Canada's global impact, telemedicine growth, new market openings, quota changes
Export Markets
🇨🇦 Canada 🇵🇹 Portugal 🇩🇰 Denmark 🇲🇰 N. Macedonia 🇪🇸 Spain 🇦🇺 Australia 🇨🇿 Czechia 🇿🇦 South Africa
Patient Markets
🇦🇺 Australia 🇩🇪 Germany 🇬🇧 UK 🇵🇱 Poland 🇧🇷 Brazil 🇫🇷 France
100% free • No credit card required
As trusted by
DIAGEO KPMG Coca-Cola BARCLAYS BNP PARIBAS AB InBev NOVARTIS Johnson & Johnson PEPSICO AXA POLITICO Bloomberg amazon CNN Business
Part of our annual market review series GDPR compliant

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?